Trial reportInternational journal of radiation oncology, biology, physics2016
Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129.
Trial report in International journal of radiation oncology, biology, physics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.International journal of radiation oncology, biology, physics · 2018Trial
- STING predicts patterns of failure in locally advanced head and neck squamous cell carcinoma.JNCI cancer spectrum · 2026Article
- Other Than Complete Response in Oropharyngeal Carcinoma: Patient and Tumor-Related Factors.Laryngoscope investigative otolaryngology · 2025Article
- Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer.Journal for immunotherapy of cancer · 2025Article
- Predictors for Success and Failure in Transoral Robotic Surgery-A Retrospective Study in the North of the Netherlands.Cancers · 2024Article
- Review of Outcomes after Salvage Surgery for Recurrent Squamous Cell Carcinoma of the Head and Neck.Cancers · 2023Review
- Article
- Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer.CA: a cancer journal for clinicians · 2023Review
- Diffusion MRI correlation with p16 status and prediction for tumor progression in locally advanced head and neck cancer.Frontiers in oncology · 2023Article
- Magnetic Resonance-Guided Radiation Therapy for Head and Neck Cancers.Current oncology (Toronto, Ont.) · 2022Review
- Review
- Use of preoperative PET-CT and survival of p16-negative oropharyngeal cancer.American journal of cancer research · 2022Article
- DUOX2, a New Biomarker for Disseminated Gastric Cancer's Response to Low Dose Radiation in Mice.Cancers · 2021Article
- Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives.Journal of clinical medicine · 2021Review
- Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma.International journal of biological sciences · 2021Review
- Incidence and outcomes of radiation-induced late cranial neuropathy in 10-year survivors of head and neck cancer.Oral oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 2 countries.
Funding
Abstract
purposeTo determine the relationship between p16 status and the regional response of patients with node-positive oropharynx cancer treated on NRG Oncology RTOG 0129. METHODS AND MATERIALS: Patients with N1-N3 oropharynx cancer and known p16 status who underwent treatment on RTOG 0129 were analyzed. Pathologic complete response (pCR) rates in patients treated with a postchemoradiation neck dissection (with p16-positive or p16-negative cancer) were compared by Fisher exact test. Patients managed expectantly were compared with those treated with a neck dissection.
resultsNinety-nine (34%) of 292 patients with node-positive oropharynx cancer and known p16 status underwent a posttreatment neck dissection (p16-positive: n=69; p16-negative: n=30). The remaining 193 patients with malignant lymphadenopathy at diagnosis were observed. Neck dissection was performed a median of 70 (range, 17-169) days after completion of chemoradiation. Neither the pretreatment nodal stage (P=.71) nor the postradiation, pre-neck dissection clinical/radiographic neck assessment (P=.42) differed by p16 status. A pCR was more common among p16-positive patients (78%) than p16-negative patients (53%, P=.02) and was associated with a reduced incidence of local-regional failure (hazard ratio 0.33, P=.003). On multivariate analysis of local-regional failure, a test for interaction between pCR and p16 status was not significant (P=.37). One-hundred ninety-three (66%) of 292 of initially node-positive patients were managed without a posttreatment neck dissection. Development of a clinical (cCR) was not significantly influenced by p16-status (P=.42). Observed patients with a clinical nodal CR had disease control outcomes similar to those in patients with a pCR neck dissection.
conclusionsPatients with p16-positive tumors had significantly higher pCR and locoregional control rates than those with p16-negative tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.